geoscience.net logo
+ Resolve Article
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter

+ Translate
+ Subscribe to Site Feed
GeoScience Most Shared ContentMost Shared Content

Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis


, : Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis. Pharmacoeconomics 10(1): 59-71

The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be efficacious, the acquisition cost of sumatriptan is over 3 times that of DHE. Total costs in each treatment group were calculated and applied independently to 11 clinical trial efficacy measures. Three of the efficacy measures showed no statistically significant difference between treatment arms, leading to a decision to use the less expensive DHE. In 4 of the efficacy measures. DHE was the obvious choice because it is more efficacious and less expensive. For the final 4 efficacy measures, where sumatriptan is more efficacious and more expensive, incremental cost-efficacy ratios were calculated to determine the additional expenditure required to achieve outcomes associated with quick relief. Depending on the efficacy variable chosen and the assumptions used in the model, the incremental cost-efficacy ratios ranged from $US4000 to $US6700 per year (1993 dollars) for each additional patient who is successfully treated with sumatriptan compared with DHE. Therefore, in a population of 100 migraineurs, an additional 13 to 22 patients would achieve these short term benefits of sumatriptan, although it would cost an additional $US88 395 annually, given the assumptions made. Because each product has unique advantages, we conclude that the more cost-efficacious product is dependent on the outcome of interest and the amount that the patient or provider is willing to pay to achieve that outcome.

US$29.90

PMID: 10160470


Other references

Petry, N.M.; Hodgins, D.C., 2012: An introduction to Addiction's new series on gambling. Addiction 107(6): 1034-1035

Cooke, W.T., 1960: Malabsorption syndrome: pathogenesis. American Journal of Clinical Nutrition 8: 167-172

Ralph, S.; Wines, B.; Payne, M.; Hatziniziriou, I.; Devenish, R.; Linnae, T., 1994: Interferon signalling deficiency in human melanoma cell lines. Journal of Cellular Biochemistry Supplement 0(18B): 243

Filip, A., 1953: Use of capillary analysis in evaluation of Galenic preparations. Ceskoslovenska Farmacie 2(9): 323-328

Ramírez-Bermúdez, Jús.; Guadamuz, A.; Alanis, P.Alvarado.; Favila, R.; Atriano, C.; Taboada, Jús.; Marrufo-Meléndez, Óscar.; Berlanga-Flores, C.; Carrillo-Mezo, R., 2014: Structural connectivity in late-onset mania. Bipolar Disorders 16(2): 208-210

Meddings, F.; Phipps, F.MacVane.; Haith-Cooper, M.; Haigh, J., 2006: Vaginal birth after caesarean section (VBAC): exploring women's perceptions. This study was designed to complement local audit data by examining the lived experience of women who elected to attempt a vaginal birth following a previous caesarean delivery. The study sought to determine whether or not women were able to exerc...

Sendler, O., 1938: Ueber ungewohn-liche Wachs-Ausscheidung der Honig-biene. Natur und Volk Frankfurt a M: 68: 87-92

Nordin, B.E.; Polley, K.J., 1987: Metabolic consequences of the menopause. A cross-sectional, longitudinal, and intervention study on 557 normal postmenopausal women. In 557 postmenopausal women bone density decreased significantly with age at 5.6 mg/ml year and significantly with years since menopause at 4.7 mg/ml year. Bone loss was more rapid in the first few years after the menopause and slowed down thereaf...

Gondal, G.; Johnson, E.; Johannessen, H-Olaf.; Hofstad, Børn., 2008: Treatment of oesophageal perforations. Esophageal perforation is a serious condition with a high mortality. Treatment is both surgical and conservative. Records were retrospectively reviewed for 22 patients (17 men), with median age 64 (30-85) years, that had been treated for esophagea...

Jurna I.; Heinz G., 1978: Enhancement by morphine of nigro spinal facilitation and inhibition. Neuroscience Letters SUPPL(1): S236